Temizoz Burcu (Burcu Temizoz) - マイポータル

基本情報

所属: ワクチン科学分野, 東京大学医科学研究所助教授 (助教授)

学位: 博士(2018年3月大阪大学)

ORCID iD: https://orcid.org/0000-0002-5189-3529
J-GLOBAL ID: 202401000079490925
researchmap会員ID: R000071983

研究キーワード

論文

An adjuvant database for preclinical evaluation of vaccines and immunotherapeutics

Yayoi Natsume-Kitatani, Kouji Kobiyama, Yoshinobu Igarashi, Taiki Aoshi, Noriyuki Nakatsu, Lokesh P. Tripathi, Junichi Ito, Johan Nyström-Persson, Yuji Kosugi, Rodolfo S. Allendes Osorio …

Cell Chemical Biology 2025年8月
Microbial dysbiosis fuels STING-driven autoinflammation through cyclic dinucleotides.

Takayuki Shibahara, Burcu Temizoz, Shiori Egashira, Koji Hosomi, Jonguk Park, Naz Surucu, Albin Björk, Erdal Sag, Takehiko Doi, Rabia Miray Kisla Ekinci …

Journal of autoimmunity 154 103434-103434 2025年6月
TLR9 plus STING Agonist Adjuvant Combination Induces Potent Neopeptide T Cell Immunity and Improves Immune Checkpoint Blockade Efficacy in a Tumor Model.

Melisa D Castro Eiro, Kou Hioki, Ling Li, Merel E P Wilmsen, Caoimhe H Kiernan, Inge Brouwers-Haspels, Marjan van Meurs, Manzhi Zhao, Harm de Wit, Dwin G B Grashof …

Journal of immunology (Baltimore, Md. : 1950) 212(3) 455-465 2024年2月1日
5,6-dimethylxanthenone-4-acetic acid (DMXAA), a partial STING agonist, competes for human STING activation.

Burcu Temizoz, Takayuki Shibahara, Kou Hioki, Tomoya Hayashi, Kouji Kobiyama, Michelle Sue Jann Lee, Naz Surucu, Erdal Sag, Atsushi Kumanogoh, Masahiro Yamamoto …

Frontiers in immunology 15 1353336-1353336 2024年
Safety and immunogenicity of a quadrivalent seasonal influenza vaccine adjuvanted with hydroxypropyl-β-cyclodextrin: A phase 1 clinical trial.

Akane Watanabe, Sumiyuki Nishida, Temizöz Burcu, Takayuki Shibahara, Takato Kusakabe, Etsushi Kuroda, Ken J Ishii, Atsushi Kumanogoh

Vaccine 40(31) 4150-4159 2022年7月29日
CpG ODN (K3)-toll-like receptor 9 agonist-induces Th1-type immune response and enhances cytotoxic activity in advanced lung cancer patients: a phase I study.

Tomoyuki Otsuka, Sumiyuki Nishida, Takayuki Shibahara, Burcu Temizoz, Masanari Hamaguchi, Takayuki Shiroyama, Keiko Kimura, Kotaro Miyake, Haruhiko Hirata, Yumiko Mizuno …

BMC cancer 22(1) 744-744 2022年7月7日
Anti-tumor immunity by transcriptional synergy between TLR9 and STING activation.

Burcu Temizoz, Kou Hioki, Shingo Kobari, Nao Jounai, Takato Kusakabe, Michelle S J Lee, Cevayir Coban, Etsushi Kuroda, Ken J Ishii

International immunology 34(7) 353-364 2022年7月4日
B cell–intrinsic TBK1 is essential for germinal center formation during infection and vaccination in mice

Michelle S.J. Lee, Takeshi Inoue, Wataru Ise, Julia Matsuo-Dapaah, James B. Wing, Burcu Temizoz, Kouji Kobiyama, Tomoya Hayashi, Ashwini Patil, Shimon Sakaguchi …

Journal of Experimental Medicine 219(2) 2022年2月7日
Machine Learning-Assisted Screening of Herbal Medicine Extracts as Vaccine Adjuvants.

Kou Hioki, Tomoya Hayashi, Yayoi Natsume-Kitatani, Kouji Kobiyama, Burcu Temizoz, Hideo Negishi, Hitomi Kawakami, Hiroyuki Fuchino, Etsushi Kuroda, Cevayir Coban …

Frontiers in immunology 13 847616-847616 2022年
Type I and II interferons toward ideal vaccine and immunotherapy.

Burcu Temizoz, Ken J Ishii

Expert review of vaccines 20(5) 527-544 2021年5月
B cell-intrinsic MyD88 signaling controls IFN-γ-mediated early IgG2c class switching in mice in response to a particulate adjuvant.

Michelle Sue Jann Lee, Yayoi Natsume-Kitatani, Burcu Temizoz, Yukiko Fujita, Aki Konishi, Kyoko Matsuda, Yoshikatsu Igari, Toshihiro Tsukui, Kouji Kobiyama, Etsushi Kuroda …

European journal of immunology 49(9) 1433-1440 2019年9月
Cyclic GMP-AMP Triggers Asthma in an IL-33-Dependent Manner That Is Blocked by Amlexanox, a TBK1 Inhibitor.

Koji Ozasa, Burcu Temizoz, Takato Kusakabe, Shingo Kobari, Masatoshi Momota, Cevayir Coban, Shuichi Ito, Kouji Kobiyama, Etsushi Kuroda, Ken J Ishii

Frontiers in immunology 10(SEP) 2212-2212 2019年
Combination and inducible adjuvants targeting nucleic acid sensors.

Burcu Temizoz, Etsushi Kuroda, Ken J Ishii

Current opinion in pharmacology 41 104-113 2018年8月
Inhaled Fine Particles Induce Alveolar Macrophage Death and Interleukin-1α Release to Promote Inducible Bronchus-Associated Lymphoid Tissue Formation.

Etsushi Kuroda, Koji Ozasa, Burcu Temizoz, Keiichi Ohata, Christine X Koo, Tomohiro Kanuma, Takato Kusakabe, Shingo Kobari, Masanori Horie, Yasuo Morimoto …

Immunity 45(6) 1299-1310 2016年12月20日
Circulating nano-particulate TLR9 agonist scouts out tumor microenvironment to release immunogenic dead tumor cells.

Yuji Kitahata, Tomohiro Kanuma, Masayuki Hayashi, Nobuyoshi Kobayashi, Koji Ozasa, Takato Kusakabe, Burcu Temizoz, Etsushi Kuroda, Hiroki Yamaue, Cevayir Coban …

Oncotarget 7(31) 48860-48869 2016年8月2日
Vaccine adjuvants as potential cancer immunotherapeutics.

Burcu Temizoz, Etsushi Kuroda, Ken J Ishii

International immunology 28(7) 329-38 2016年7月
Species-dependent role of type I IFNs and IL-12 in the CTL response induced by humanized CpG complexed with β-glucan.

Kouji Kobiyama, Burcu Temizoz, Tomohiro Kanuma, Koji Ozasa, Masatoshi Momota, Takuya Yamamoto, Taiki Aoshi, Etsushi Kuroda, Ken J Ishii

European journal of immunology 46(5) 1142-51 2016年5月
Novel adjuvants

Burcu Temizoz, Etsushi Kuroda, Kouji Kobiyama, Taiki Aoshi, Ken J. Ishii

Immunotherapy of Cancer: An Innovative Treatment Comes of Age 247-260 2016年2月22日
TLR9 and STING agonists synergistically induce innate and adaptive type-II IFN.

Burcu Temizoz, Etsushi Kuroda, Keiichi Ohata, Nao Jounai, Koji Ozasa, Kouji Kobiyama, Taiki Aoshi, Ken J Ishii

European journal of immunology 45(4) 1159-69 2015年4月

共同研究・競争的資金等の研究課題

Potential link between dysbiosis and STING-associated autoinflammation and implications for autoinflammatory diseases

日本学術振興会科学研究費助成事業若手研究 2022年4月 - 2024年3月

TEMIZOZ BURCU
Immunological Mechanisms of Synergistic Anti-cancer Activities by Activation of TLR9 and STING

Japan Society for the Promotion of Science Grants-in-Aid for Scientific Research Grant-in-Aid for Early-Career Scientists 2019年4月 - 2021年3月

TEMIZOZ BURCU